Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25884614 | 0.77 | HCAR3 (0.33) | HCAR3ALOX15TSHRCASP1 | |
| SCHEMBL23835830 | 0.73 | LIMK1 (0.42) | LIMK1CDK2CCNE1CDK5MEN1 | |
| SCHEMBL25571558 | 0.71 | LRRK2 (0.37) | HCAR3LIMK1CDK5FDPSTRPM8 | |
| SCHEMBL17248050 | 0.70 | MAPK14 (0.50) | CDK2CCNE1CDK5MAPK14FDPS | |
| SCHEMBL26546522 | 0.69 | GAA (0.35) | HCAR3CDK2MEN1KMT2AL3MBTL1 | |
| SCHEMBL23835831 | 0.68 | HDAC1 (0.47) | LIMK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17206690 | 0.67 | — | — | |
| SCHEMBL15357789 | 0.67 | FDPS (0.32) | MEN1KMT2AFDPSTRPM8MAPK1 | |
| SCHEMBL16708654 | 0.67 | HCAR3 (0.36) | HCAR3CDK2CCNA2TRPM8MAPK1 | |
| SCHEMBL14099759 | 0.67 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9982016-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20180094029-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | ALCON RESEARCH, LTD. | 2018-04-05 | — | — | US | disclosed |
| US-20180094029-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | ALCON RESEARCH, LTD. | 2018-04-05 | — | — | US | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20160194357-A1 | Novel NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9187525-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-8551938-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8546523-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | NPR1, NPR3, NPBWR1 | HCAR3 130/4885LIMK1 3680/4885CDK2 4325/4885 |
| US-20180094029-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | HCAR3 121/4885LIMK1 3934/4885CDK2 4629/4885 |
| US-20170313743-A1 | NPR-B Agonists | NPR1, NPR3, NPBWR1 | HCAR3 107/4885LIMK1 4044/4885CDK2 4353/4885 |
| US-20160194357-A1 | Novel NPR-B Agonists | NPR1, NPR3, NPBWR1 | HCAR3 130/4885LIMK1 3680/4885CDK2 4325/4885 |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | NPR1, NPR3, NPBWR1 | HCAR3 130/4885LIMK1 3680/4885CDK2 4325/4885 |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | HCAR3 121/4885LIMK1 3934/4885CDK2 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.